Evidence map›Paper›PMID 40556805›Full record

ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2024

Hepatitis C Screening in Community Pharmacies-A Feasibility and Knowledge Transfer Study: PHARMA-C.

Rose Prévost, Émilie Roy-St-Pierre, Kamilia Idir, Azam Khodamoradi, Frédéric Provost, Dominic Martel, Nancy L Sheehan, Valérie Martel-Laferrière, Rachel Therrien

Abstract read
In one paragraph

Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rose PrévostCentre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.ORCID https://orcid.org/0009-0006-3106-8149
Émilie Roy-St-PierreFaculté de Pharmacie, Université de Montréal, Montréal, Canada.ORCID https://orcid.org/0009-0005-7575-5146
Kamilia IdirCentre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.ORCID https://orcid.org/0009-0008-1893-8984
Azam KhodamoradiCentre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.ORCID https://orcid.org/0009-0007-2537-7022
Frédéric ProvostFaculté de Pharmacie, Université de Montréal, Montréal, Canada.ORCID https://orcid.org/0009-0006-9633-4161
Dominic MartelCentre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.ORCID https://orcid.org/0000-0002-8384-8263
Nancy L SheehanFaculté de Pharmacie, Université de Montréal, Montréal, Canada.ORCID https://orcid.org/0000-0001-9060-1560
Valérie Martel-LaferrièreCentre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.ORCID https://orcid.org/0000-0001-7973-8582
Rachel TherrienCentre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.ORCID https://orcid.org/0000-0003-4170-017X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: New strategies are needed to increase access to hepatitis C virus (HCV) testing. This study evaluated the feasibility of HCV rapid testing in community pharmacies in Quebec (Canada) and assessed knowledge transfer (KT). Methods: PHARMA-C was a 6-month (February to September 2022) prospective KT study. Community pharmacists (CPs) were recruited and trained to identify HCV risk factors, conduct rapid antibody tests (OraQuickHCV), and pre- and post-test counselling, and link positive cases to care. Health care users (HUs) were included according to HCV risk factors. An advisory committee and focus groups provided guidance, feedback, and identified barriers and facilitators to improve the program. A pre- and post-intervention questionnaire was completed by CPs to assess feasibility and KT. HUs completed a satisfaction survey. Results: A total of 32 CPs were included and 16 performed 101 HCV tests. Two positive cases were identified and linked to care. Comparison of pre- and post-intervention surveys shows that pharmacists felt more confident in identifying HCV risk factors, communicating information to patients related to HCV, and performing the HCV screening test at the end of the intervention. HCV screening in pharmacies was considered feasible by 77.8% of CPs. The intervention lasted approximately 22 minutes. The main barriers to implementation were lack of time and fear of stigmatizing HUs. Promotional material and training were the main facilitators. Conclusion: HCV point-of-care testing by CPs is feasible in Quebec. Expanding pharmacists' scope of practice to include HCV screening and increasing pharmacists' role in the HCV care cascade is encouraged in order to further efforts toward HCV elimination.

Indexed as

community pharmacistscommunity pharmacy serviceshepatitis C (HCV)knowledge transferpharmaciespoint-of-care testingrapid antibody HCV test

Identifiers

PMID40556805
PMCPMC12169432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.